

CY 2024 Real World Testing Results Report for Nextech Select and Nexcloud; and Nextech Select and Nexcloud with NewCropRx

Executive Summary

This is the documentation of the results of our real-world testing based on our 2024 Real World Test Plan for CY 2024 for Nextech’s certified EHR solution, and we will be testing on our most current certified version. It provides the real-world test measurements and metrics that meet the intent and objectives of ONC’s Condition of Certification and Maintenance of Certification requirement for real world testing (§ 170.405 Real world testing) to evaluate compliance with the certification criteria and interoperability of exchanging electronic health information (EHI) within the care and practice setting which it is targeted for use.

As ONC has stated in its rule, “The objective of real-world testing is to verify the extent to which certified health IT deployed in operational production settings is demonstrating continued compliance to certification criteria and functioning with the intended use cases as part of the overall maintenance of a health IT’s certification.” We have worked toward this objective in designing our test plan and its subsequent real world testing measurements and metrics.

This document reports the results of the final testing measurements and metrics used to demonstrate our product interoperability within production settings. Within each measure, we document testing methodology, associated ONC criteria, justification for measurement, outcomes from the testing, and care settings applied for this measure. We also include the number of clients to use for testing, including how our test cases were created, our selected methodology, our general approach and justification for decisions and any variances from the CY 2024 Real World Test Plan.

A table of contents with hyperlinks is provided later in the plan for quick access to any document section, including the testing measurements and metrics found at the end of this document. Our signed attestation of compliance with the real-world testing requirements is on the following page.

Developer Attestation

This Real-World Testing (RWT) Results Report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this report is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Simmie Border

Authorized Representative Email: s.border@nextech.com

Authorized Representative Phone: 813-964-7117

Authorized Representative Signature: *Simmie Border*

DATE: January 29, 2025

Table of Contents

Executive Summary.....	1
Developer Attestation.....	2
General Information	4
Relied-Upon Software.....	4
Changes to Original Plan.....	5
Withdrawn Products.....	5
Timeline and Milestones for Real World Testing CY 2023.....	6
Standards Version Advancement Process (SVAP) Updates.....	8
Real-World Testing Measurements.....	9
Testing Methodologies	9
Number of Clients Sites	9
Care and Practice Settings Targeted.....	10
Measures Tested.....	11
RWT #1: Number of Transition of Care C-CDAs Successfully Sent	11
RWT #2: Number of C-CDAs Received and/or Incorporated.....	13
RWT #3: Number of NewRx Prescriptions Messages Successfully Sent.....	15
RWT #4: Number of Patients Given Access to Portal	17
RWT #6: Number of Direct Messages Successfully Sent	19
RWT #7: Number of Patient Batch Exports Run	21
RWT #8: Number of Quality Measures Successfully Reported on to CMS.....	23
RWT #9: Number of API Client Applications Successfully Connected to our API Service	25

General Information

- Plan Report ID Number: Nextech_RWTResults_2024
- Developer Name: Nextech
- Product Name(s): Nextech Select and Nexcloud; and Nextech Select and NexCloud with NewCropRx
- Version Numbers(s): 17, 18
- Certified Health IT Criteria: 315(b)(1)-(3), (b)(6), (c)(1)-(3), (e)(1), (g)(7)-(10), (h)(1). Criterion (b)(10) was added in December 2023 but not included in 2023 RWT.
- Product Name(s) and Version Number(s) with (CHPL) ID(s) and Link(s):
- Nextech Select and Nexcloud, Version 17:
 - <https://chpl.healthit.gov/#/listing/11028>
- Nextech Select and Nexcloud, Version 18:
 - <https://chpl.healthit.gov/#/listing/11478>
- Nextech Select and Nexcloud with NewCropRx, Version 17:
 - <https://chpl.healthit.gov/#/listing/11029>
- Nextech Select and Nexcloud with NewCropRx, Version 18:
 - <https://chpl.healthit.gov/#/listing/11477>
- Developer Real-World Testing Page URL: <https://www.nextech.com/compliance/onc-health-it/nextech>

Relied-Upon Software

Health IT Module	Relied-Upon Software	Testing Measure	Associated Criteria
Nextech Select and NexCloud, versions 17 and 18	Secure Exchange Solutions SES Direct	RWT Measure #1 – Number of Transition of Care C-CDAs Successfully Sent RWT Measure #6 Number of Direct Messages Successfully Sent	315(b)(1) 315(h)(1)
Nextech Select and NexCloud with NewCropRX, versions 17 and 18	NewCropRx	RWT Measure #3 Number of NewRx Messages Successfully Sent	315(b)(3)

Summary of Change [Summarize each element that changed between the plan and actual execution of Real World Testing]		Reason	Impact [Describe what impact change had on the execution of your RWT Activities]
N/A		N/A	N/A
Nextech Select and NexCloud with NewCropRX, versions 17 and 18	Secure Exchange Solutions SES Direct	RWT Measure #1 – Number of Transition of Care C-CDAs Successfully Sent RWT Measure #6 Number of Direct Messages Successfully Sent	315(b)(1) 315(h)(1)

Changes to Original Plan

No changes were made to the original RWT plan.

Withdrawn Products

If any products were withdrawn within the past year that were previously included in the Real World Testing Plan, provide the following information:

The products listed below were withdrawn on 12/31/2022 and replaced with the Cures update certified version. No data in the Real World Testing results were captured from withdrawn products.

Withdrawn Product Name(s) and Version Number(s) with (CHPL) ID(s) and Link(s):

- Nextech Version 16
 - ONC-ACB Certification ID: 15.04.04.2051.Ntec.16.08.1.210524
 - <https://chpl.healthit.gov/#/listing/10638>
- Nextech with NewCrop Rx Version 16
 - ONC-ACB Certification ID: 15.04.04.2051.Next.16.07.1.210524
 - <https://chpl.healthit.gov/#/listing/10639>

- Nextech Version 15
 - ONC-ACB Certification ID: 15.04.04.2051.Ntec.15.07.1.200610
 - <https://chpl.healthit.gov/#/listing/10409>
- Nextech with NewCrop Rx Version 15
 - ONC-ACB Certification ID: 15.04.04.2051.Ntec.15.07.1.200610
 - <https://chpl.healthit.gov/#/listing/10408>
- Nextech with NewCrop Rx Version 14
 - ONC-ACB Certification ID: 15.04.04.2051.Next.14.05.1.181119
 - <https://chpl.healthit.gov/#/listing/9750>
- Nextech with NewCrop Rx Version 12.9
 - ONC-ACB Certification ID: 15.04.04.2051.Next.29.03.1.180814
 - <https://chpl.healthit.gov/#/listing/9605>
- Nextech with NewCrop Rx Version 12.8
 - ONC-ACB Certification ID: 15.04.04.2051.Next.29.03.1.180814
 - <https://chpl.healthit.gov/#/listing/9604>
- Nextech with NewCrop Rx Version 12.7
 - ONC-ACB Certification ID: 15.04.04.2051.Next.29.03.1.180814
 - <https://chpl.healthit.gov/#/listing/9603>
- Nextech with NewCrop Rx Version 12.6
 - ONC-ACB Certification ID: 15.04.04.2051.Next.12.00.1.170929
 - <https://chpl.healthit.gov/#/listing/8882>

Nextech intends to withdraw Nextech Select and Nexcloud, Version 17 and Nextech Select and Nexcloud with NewCropRx, Version 17 in 2025. For the CY 2024 Real World Testing activities performed for 2024 reporting, version 17 is still certified and active.

Timeline and Milestones for Real World Testing CY 2024

Our current proposed timeline for real-world testing is described below. As we will complete development work and rollout of our Cures criteria updates, we will review our RWT dates to adjust for these changes.

- 1Q-2024: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have enough clients committed for real-world testing by the end of 1Q-2024.
- 2Q-3Q 2024. During the 2nd and 3rd quarters of CY 2024, the real-world testing with clients will be scheduled and performed. It is expected that a preparatory call will be done with clients to prepare them for testing activities. Results will be documented in the test results section of the test methods and ultimately used to build the test report. If any non-compliances are observed, we will notify the ONC-ACB of the findings and make the necessary changes required.

- 4Q-2024. During the last quarter of the year, the CY 2024 real world test plan will be completed according to ONC and ONC-ACB requirements and expectations. Test plan will be prepared for submission before the end of the year.

[ONC Template Instructions: Include a list of key milestones that were met during the Real World Testing process. Include details on how and when the developer implemented measures and collected data. Key milestones should be relevant and directly related to outcomes discussed. For each key milestone, describe when Real World Testing began in specific care settings and the date/timeframe during which data was collected.]

Although Real World Testing activities planned for Q1-Q3 CY 2024 were delayed due to Cures Act development, all activities were completed in Q4.

Key Milestone	Care Setting	Date/Timeframe
Gather participating clients (Q1 milestone)	All	Jan-March 2024
Schedule and perform Real World Testing (Q2 and Q3 Milestones)	All	June 2024 through January 2025
Complete 2025 Real World Test Plan	All	Submitted to ONC-ACB Drummond on 11/25/2024

Standards Version Advancement Process (SVAP) Updates

For CY 2024, we did not make any version updates on approved standards through the SVAP process. We implemented USCDI v1 in our C-CDAs and API support during CY 2023 Cures Act development and implementation. We have rolled out the new Cures version to all Cloud customers and are working on rollout to all on-premises customers.

Nextech will implement USCDI v3 in 2025 in accordance with HTI-1 requirements, which will be appropriately reflected in future Real World Testing plans and results.

Standard (and version)	N/A
Updated certification criteria and associated product	N/A
Health IT Module CHPL ID	N/A
Method used for standard update	N/A
Date of ONC-ACB notification	N/A
Date of customer notification (SVAP only)	N/A
Conformance measure	N/A
USCDI-updated certification criteria (and USCDI version)	N/A

STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

Both required and voluntary standards updates must be addressed in the Real World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made. Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).

• ☐ Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below.

• ☒ **XXXXX** No, none of my products include these voluntary standards.

Standard (and version)	N/A
Updated certification criteria and associated product	N/A
CHPL Product Number	N/A

Real-World Testing Measurements

The measurements for our real-world testing plan are described below. Each measurement contains:

- Associated ONC criteria
- Testing Methodology used
- Description of the measurement/metric
- Justification for the measurement/metric
- Expected and actual outcomes in testing for the measurement/metric
- Number of client sites to use in testing (if applicable)
- Care settings which are targeted with the measurement/metric

In each measurement evaluated, we elaborate specifically on our justification for choosing this measure and the expected and actual outcomes. All measurements were chosen to best evaluate compliance with the certification criteria and interoperability of exchanging electronic health information (EHI) within the certified EHR.

Testing Methodologies

For each measurement, a testing methodology is used. For our test plan, we use the following methodologies.

Reporting/Logging: This methodology uses the logging or reporting capabilities of the EHR to examine functionality performed in the system. A typical example of this is the measure reporting done for the automated measure calculation required in 315(g)(2), but it can also be aspects of the audit log or customized reports from the EHR. This methodology often provides historical measurement reports which can be accessed at different times of the year and evaluate interoperability of EHR functionality, and it can serve as a benchmark for evaluating real-world testing over multiple time intervals.

Compliance and/or Tool: This methodology uses inspection to evaluate if EHR is compliant to the ONC criteria requirements. It can be done through 1-v-1 inspection testing or utilize various tools to measure or evaluate compliance and interoperability. If an EHR Module capability is not widely used in production by current users, compliance inspection can provide assurance criteria is working as previously certified.

Number of Clients Sites

Within each measure, we note the minimum number of clients or client sites we plan to use for this measure evaluation. The numbers vary depending on the methodology as well as overall use of the associated EHR Module criteria by our users. For criteria that are not widely used by

our customer base, we may test the respective measure in our own production-sandbox environment given lack of customer experience with the criteria functionality.

Care and Practice Settings Targeted

Nextech EHR is primarily targeted for Ophthalmology, Dermatology, and Plastic Surgery settings, and our measures were designed to collectively address these care settings. In each measure, we note if any adjustments should be made for the various care settings.

Measures Tested

RWT #1: Number of Transition of Care C-CDAs Successfully Sent

Associated Criteria: 315(b)(1)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many C-CDAs are created and successfully sent from the EHR Module to a 3rd party via Direct messaging during a transition of care event over the course of a given interval.

The interval for this measure will be for a minimum of three (3) consecutive months during the calendar year. This will ensure sufficient time to gauge and measure interoperability.

Measurement Justification

This measure will provide a numeric value to indicate both how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that the EHR can create a C-CDA patient summary record, including ability to record all required clinical data elements, and by sending the C-CDA patient summary record, the EHR demonstrates successful interoperability of an exchanged patient record with a 3rd party. This measurement shows support for Direct Edge protocol in connecting to a HISP for successful transmission.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that the EHR can create the C-CDA patient summary record, including record required clinical data elements. In sending the C-CDA patient summary record, the EHR will demonstrate the ability to confirm successful interoperability of an exchanged patient record with a 3rd party, including support for Direct Edge protocol in connecting to a HISP. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real-world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(b)(1)		
Test Name	Number of Transition of Care C-CDAs Successfully Sent		
Measure Used	How many C-CDAs are created and successfully sent from the EHR Module to a 3 rd party via Direct messaging during a transition of care event over the course of a given interval.		
Data Collection Method	Promoting Interoperability (formerly Meaningful Use) Reports		
Testing Results	Results	Variances	Comments
Client #1	11		
Client #2	0		Small practice PI hardship
Client #3	0		Small practice PI hardship
Client #4	0		Small practice PI hardship
Client #5		*see note below	

*Customer is on-premises (Nextech Select) and was running version 17.6. While this is a certified version, Nextech had to release an update to the report .exe used for generating Promoting Interoperability reports. This update required on-premises customers to update to the dot version of 18, which was communicated to customers. At the time of testing, this customer had not yet updated, so the reports used to collect Real World Testing data were not available.

RWT #2: Number of C-CDAs Received and/or Incorporated

Associated Criteria: 315(b)(2)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many C-CDAs are successfully received and/or incorporated upon receipt from a 3rd party via direct messaging during a transition of care event over the course of a given interval.

The interval for this measure will be for a minimum of three (3) consecutive months during the calendar year. This will ensure sufficient time to gauge and measure interoperability.

Measurement Justification

This measure will provide a numeric value to indicate both the how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that the EHR can receive a C-CDA patient summary record, and by incorporating the C-CDA patient summary record, the EHR demonstrates successful interoperability of problems, medications, and medication allergies of patient record with a 3rd party. This measurement shows support for Direct Edge protocol in connecting to a HISP for successful transmission.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that they can receive a C-CDA patient summary record. In incorporating the C-CDA patient summary record, the EHR will demonstrate successful interoperability of problems, medications, and medication allergies of patient record with a 3rd party, including support for Direct Edge protocol in connecting to a HISP. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real-world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(b)(2)		
Test Name	Number of C-CDAs Received and/or Incorporated		
Measure Used	How many C-CDAs are successfully received and/or incorporated upon receipt from a 3rd party via Direct messaging during a transition of care event over the course of a given interval.		
Data Collection Method	Promoting Interoperability (formerly Meaningful Use) Reports		
Results	Results	Variances	Comments
Client #1	0		Did not perform activity during the selected testing dates 1/1/24 to 3/31/24
Client #2	0		Small practice PI hardship
Client #3	3		Small practice PI hardship
Client #4	2		Small practice PI hardship
Client #5		*see note below	

*Customer is on-premises (Nextech Select) and was running version 17.6. While this is a certified version, Nextech had to release an update to the report .exe used for generating Promoting Interoperability reports. This update required on-premises customers to update to the dot version of 18, which was communicated to customers. At the time of testing, this customer had not yet updated, so the reports used to collect Real World Testing data were not available.

RWT #3: Number of NewRx Prescriptions Messages Successfully Sent

Associated Criteria: 315(b)(3)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a given interval. It applies only to the Nextech with NewCropRx product, as DrFirst maintains (b)(3) certification of their product.

The interval for this measure will be for a minimum of three (3) consecutive months during the calendar year. This will ensure sufficient time to gauge and measure interoperability.

Measurement Justification

This measure will provide a numeric value to indicate both how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that the EHR can create a NewRx SCRIPT electronic prescription message and transmit it to a pharmacy, typically via the Surescripts Network.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that the EHR can create the NewRx message and send over a production network, like the Surescripts Network, to a pharmacy. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real-world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(b)(3) - for Nextech with NewCrop only		
Test Name	Number of NewRx Prescription Messages Successfully Sent		
Measure Used	How many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a 3-month interval.		
Data Collection Method	Promoting Interoperability (formerly Meaningful Use) Reports		
Results	Results	Variances	Comments
Client #1	N/A - DrFirst		25,289 sent for DrFirst
Client #2	N/A - DrFirst		2,947 sent for DrFirst
Client #3	N/A - DrFirst		525 sent for DrFirst
Client #4	3,460		NewCrop customer
Client #5		*see note below	NewCrop customer

*Customer is on-premises (Nextech Select) with NewCrop and was running version 17.6. While this is a certified version, Nextech had to release an update to the report .exe used for generating Promoting Interoperability reports. This update required on-premises customers to update to the dot version of 18, which was communicated to customers. At the time of testing, this customer had not yet updated, so the reports used to collect Real World Testing data were not available.

RWT #4: Number of Patients Given Access to Portal

Associated Criteria: 315(e)(1)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many patients are given login access to their patient portal account over the course of a given interval.

The interval for this measure will be for a minimum of three (3) consecutive months during the calendar year. This will ensure sufficient time to gauge and measure interoperability.

Measurement Justification

This measure will provide a numeric value to indicate how often this interoperability feature is being used. An increment to this measure indicates that the EHR can supply patient health data to the patient portal and provide an account for the patient to use in accessing this data.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that the EHR can submit patient health data to the patient portal on a regular and consistent basis as well provide an account for the patient to use in accessing this data. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real-world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real-world interoperability.

Measurement Actual Outcome

Element Tested	315(e)(1)		
Test Name	Number of Patients Given Access to Portal		
Measure Used	How many patients are given login access to their patient portal account over the course of a given interval.		
Data Collection Method	Promoting Interoperability (formerly Meaningful Use) Reports		
Results	Results	Variances	Comments
Client #1	14,991	n/a	
Client #2	1,267	n/a	Small practice PI hardship
Client #3	673	n/a	Small practice PI hardship
Client #4	4,930	n/a	Small practice PI hardship
Client #5		*see note below	

*Customer is on-premises (Nextech Select) and was running version 17.6. While this is a certified version, Nextech had to release an update to the report .exe used for generating Promoting Interoperability reports. This update required on-premises customers to update to the dot version of 18, which was communicated to customers. At the time of testing, this customer had not yet updated, so the reports used to collect Real World Testing data were not available.

RWT #6: Number of Direct Messages Successfully Sent

Associated Criteria: 315(h)(1)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many Direct messages were successfully sent from the EHR Module to a 3rd party over the course of a given interval.

The interval for this measure will be for a minimum of three (3) consecutive months during the calendar year. This will ensure sufficient time to gauge and measure interoperability.

Measurement Justification

This measure will provide a numeric value to indicate both how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that the EHR can create a direct message and demonstrates successful interoperability of an exchanged message with a 3rd party.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that the EHR can be authenticated with DirectTrust, create a direct message, and demonstrate interoperability of an exchanged message with a 3rd party. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real-world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(h)(1)		
Test Name	Number of Direct Messages Successfully Sent		
Measure Used	how many Direct messages were successfully sent from the EHR Module to a 3rd party over the course of a 3 month interval.		
Data Collection Method	Count		
Results	Results	Variances	Comments
Client #1	0		None during RWT reporting period. The exact count is not obtainable as the Direct Message outbox does not include a Count feature, but can be measured using the outgoing referral PI measure.
Client #2	0		Small practice PI hardship
Client #3	0		Small practice PI hardship
Client #4	0		Small practice PI hardship
Client #5 Sandbox – 964248	1		Tested for functionality

Since Direct Message requires a Direct Message license and address, it is challenging to test in sandbox environments. However, we are able to demonstrate functionality despite low customer utilization from our selected RWT test clients using a test production environment 964248 as indicated above.

RWT #7: Number of Patient Batch Exports Run

Associated Criteria: 315(b)(6)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many batch exports of C-CDAs were successfully performed by the EHR Module over the course of a given interval.

The interval for this measure will be three (3) months.

Measurement Justification

This measure will provide a numeric value to indicate both how often this interoperability feature is being used as well as its compliance with the requirement. An increment to this measure indicates that the EHR can create a batch export of multiple C-CDA patient summary records.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that the EHR can create a batch export of multiple C-CDA patient summary records, which can be used in means of health IT interoperability. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality. We will document any errors and investigate them as necessary.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(b)(6)		
Test Name	Number of Patient Batch Exports Run		
Measure Used	How many batch exports of C-CDAs were successfully performed by the EHR Module over the course of a 3-month interval.		
Data Collection Method	Count		
Results	Results	Variances	Comments
Client #1	0		Client did not need to perform batch export of patients; reiterated where client can access educational resources on the functionality.
Client #2	0		Same as above
Client #3	0		Same as above
Client #4	0		Same as above

Since our clients selected for testing did not perform this function, the measure was tested using an internal sandbox environment. Testing demonstrates continued functionality of the Batch Export.

Data Collection Method	Test databases (database number/license key)		
Client	Results	Variances	Comments
Test #1 (964919)	1 export with 20+ files	NewCrop	Successful
Test #3 (965127)	1 export with 10 files	DrFirst	Successful

RWT #8: Number of Quality Measures Successfully Reported on to CMS

Associated Criteria: 315(c)(1)-(c)(3)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many eCQM quality measures were successfully reported on by the EHR Module to CMS over the course of a given interval.

The interval for this measure will be based on CMS submission window.

Measurement Justification

This measure will provide a count and list of electronic clinical quality measures (eCQMs) which are calculated and submitted to CMS for a given program, like MIPS. Clinical quality measures are only used for the respective CMS programs and any production measures should utilize submission to CMS. Because CQM criteria, 315(c)(1)-(c)(3), all work collectively together in the eCQM functionality of the EHR Module, this measurement is used for all three.

Measurement Expected Outcome

The measurement will a count and list of eCQMs submitted to CMS over a given interval. We will utilize various reports and audit logs to determine our measure count.

A successful measure submission indicates compliance to the underlying ONC criteria. It will show that the EHR can do calculations on the eCQM and that they are accepted by CMS. Successfully completing this measure also implies users have a general understanding of the EHR functional operations for this EHR Module and an overall support for the user experience while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality. We will document any errors and investigate them as necessary.

We will use the measure result to establish a historic baseline of expected interoperability use so it can be used in subsequent real world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(c)(1) – (c)(3)		
Test Name	Number of Quality Measures Successfully Reported on to CMS		
Measure Used	How many eCQM quality measures were successfully reported on by the EHR Module to CMS over the course of the CMS submission window.		
Data Collection Method	Count		
Results	Results	Variances	Comments
Client #1	6	n/a	
Client #2	6	n/a	
Client #3	8	n/a	
Client #4	6	n/a	
Client #5			

RWT #9: Number of API Client Applications Successfully Connected to our API Service

Associated Criteria: 315(g)(7)-(g)(10)

Testing Methodology: Reporting/Logging

Measurement Description

This measure is tracking and counting how many successful 3rd party API client applications can access patient data elements via our API over the course of a given interval.

The interval for this measure will be three (3) months.

Measurement Justification

This measure is counting how many API applications can be registered, authenticated, and actively working with our EHR. The metric will provide a numeric value to indicate both how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that a 3rd party application can be registered and authenticated with our EHR and then can successfully query the clinical resources of the patient health record via the API interface and thus demonstrate API interoperability.

Measurement Expected Outcome

The measurement will produce numeric results over a given interval. We will utilize various reports and audit logs, to determine our measure count.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that a 3rd party client can be authenticated, that the patient record can be properly identified and selected, and that the EHR can make patient data accessible via its API interface. Successfully completing this measure also implies the public API documentation is accurate and sufficient for 3rd parties to connect and use the API while not completing this measure may indicate lack of understanding or possibly lack of use or need for this functionality. We will document any errors and investigate them as necessary.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real world testing efforts.

Care Settings and Number of Clients Site to Test

We designed this measure to test the Ophthalmology, Dermatology, and Plastic Surgery settings that we support and target. We will test a minimum of three (3) client practice sites(s) from these settings. This number covers a sufficient percentage of existing practices to provide a viable sample of users of the certified EHRs to demonstrate real world interoperability.

Measurement Actual Outcome

Element Tested	315(g)(7)-(g)(10)		
Test Name	Number of API Client Applications Successfully Connected to our API Service		
Measure Used	How many successful 3rd party API client applications can access patient data elements via our API over the course of a 3-month interval.		
Data Collection Method	Count		
Results	Results	Variances	Comments
Client #1	0		Customer not currently using any API connections
Client #2	0		Customer not currently using any API connections
Client #3	0		Customer not currently using any API connections
Client #4	0		Customer not currently using any API connections
Client #5	0		Customer not currently using any API connections
Test #1 – 965127	3	10 Additional SMART on FHIR app connections available	Functioning/Success

Since our clients selected for testing did not connect any APIs, the measure was tested using an internal sandbox environment. Testing indicated above demonstrates continued functionality of the API connections.